Bain Capital, Mitsubishi Tanabe Pharma and Japan

Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group.
Bain Capital to Buy Mitsubishi Chemical’s Pharma Business for More Than $3 Billion
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.
Bain Capital buys Japanese pharma for $3.3B
Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to “accelerate the development and approval of innovative medicines in the Japanese market.
Bain buys Japanese pharma Mitsubishi Tanabe for $3.4bn
US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare sector in recent years.
Bain to acquire Mitsubishi Tanabe Pharma in US$3.3 billion deal
Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. Read more at The Business Times.
Bain Is Said to Near $3 Billion Deal for Mitsubishi Pharma Unit
Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter said, adding to a dealmaking boom in Japan.
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") in a carve-out transaction from Mitsubishi Chemical Group Corporation.
Mitsubishi Chemical to sell drug unit to Bain in $3.36 billion deal
Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it seeks to streamline its portfolio.
M&A News: Bain Capital Buys 350-Year-Old Japanese Drugs Firm for $3.4 billion
Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...
Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine ...